December 16, 2025 — Pfizer Inc. (NYSE:PFE) has provided its full-year 2026 guidance and revised its full-year 2025 revenue guidance, while reaffirming other components of its 2025 financial guidance.
Pfizer anticipates full-year 2026 revenues to be in the range of $59.5 to $62.5 billion. Full-year 2025 revenue guidance is revised to approximately $62.0 billion from the previous range of $61.0 to $64.0 billion.
The 2026 revenue guidance includes an expected $1.5 billion decrease in revenues from COVID-19 products, and an approximate $1.5 billion negative revenue impact due to certain products experiencing loss of exclusivity (LOE).
Pfizer anticipates full-year 2026 Adjusted SI&A expenses to be between $12.5 and $13.5 billion, and Adjusted R&D expenses to be between $10.5 and $11.5 billion. Adjusted diluted EPS is expected to be in the range of $2.80 to $3.00.
Pfizer will host a live conference call and webcast today, December 16, 2025, at 8:00 AM EST.
Source: Pfizer Inc.
